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Abstract
Background—Metabolic regulation plays a significant role in energy homeostasis, and
adolescence is a crucial life-stage for the development of cardiometabolic disease (CMD).

Author Manuscript

Objectives—This study aims to investigate the genetic determinants of metabolic biomarkers—
adiponectin, leptin, ghrelin, and orexin—and their associations with CMD risk factors.
Methods—We characterized the genetic determinants of the biomarkers among Hispanic/Latino
adolescents of the Santiago Longitudinal Study (SLS) and identified the cumulative effects of
genetic variants on adiponectin and leptin using biomarker polygenic risk scores (PRS). We further
investigated the direct and indirect effect of the biomarker PRS on downstream body fat percent
(BF%) and glycemic traits using structural equation modeling.

Author Manuscript

Results—We identified putatively novel genetic variants associated with the metabolic
biomarkers. A substantial amount of biomarker variance was explained by SLS-specific PRS,
and the prediction was improved by including the putatively novel loci. Fasting blood insulin and
insulin resistance were associated with PRS for adiponectin, leptin, and ghrelin, and BF% was
associated with PRS for adiponectin and leptin. We found evidence of substantial mediation of
these associations by the biomarker levels.
Conclusion—The genetic underpinnings of metabolic biomarkers can affect the early
development of CMD, partly mediated by the biomarkers.

INTRODUCTION

Author Manuscript

Obesity in early life and subsequent CMD is a major public health concern. In 2015-2016
in the US, one out of five adolescents aged 12-19 years were affected by obesity1 with a
prevalence of 25.8% among self-identified Hispanic/Latino (H/L) youth (aged 2-19 years)
compared to 14.1% among non-Hispanic white youth.1 Such alarming data are not restricted
to the US H/L population, as many self-identified H/L populations in South and Central
America are also suffering. For example, Chilean citizens also suffer from an increasing
burden of obesity due to the epidemiological and nutritional transition that began in the
1980s.2,3
Energy homeostasis is particularly critical in obesity biology4 since its related hormones
play significant roles in balancing energy expenditure and energy intake by exchanging
physiological information between the central nervous system and other parts of the body.4,5
In this regard, appetite-related metabolic hormones function as signaling molecules, and
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malfunction of this system may interrupt energy homeostasis and consequently contribute to
the development of obesity.
Four such metabolic hormones – adiponectin, leptin, ghrelin, and orexin –are involved
in diverse cardiometabolic pathways. Adiponectin is well-known for its protective roles
in appetite regulation, energy metabolism, diabetes, and inflammation.6 Leptin shows
anorexigenic and proinflammatory roles; individuals with obesity tend to have higher levels
of circulating leptin together with leptin resistance.7 Ghrelin is an appetite stimulating
gut hormone that has been associated with glucose metabolism, which is closely linked
to diabetes.8–11 Orexin is a hypothalamic neuropeptide that regulates feeding behaviors
and arousal status12–14 and is ubiquitously expressed in different body sites15, including
plasma.16

Author Manuscript

There is a paucity of information on the genetic determinants of metabolic biomarkers,
particularly among adolescents and in H/L. Such work is critical as H/L have continental
ancestry and admixture that is different than that found in European populations.
Moreover, the interrelations among the genetic underpinnings of metabolic biomarkers,
phenotypic variability, and downstream CMD risk factors (e.g., body fat percent (BF%) and
insulin resistance (IR)) among adolescents have also been understudied. Previous studies
have revealed that some obesity-associated genetic factors are associated with appetite
regulation17,18 and mendelian randomization studies have suggested causal relationships
between metabolic biomarkers and CMD risk factors. However, studies focusing on
the mediating roles of metabolic biomarkers in the relationship between the genetic
underpinnings of metabolic biomarkers and CMD risk factors are lacking.

Author Manuscript

We sought to address these important gaps in the literature by first, describing the known
and novel large-effect genetic determinants of the four metabolic biomarkers among H/L
adolescents (Figure S1). Second, assessing the influence of aggregated genetic contributions
to each biomarker by constructing polygenic risk scores (PRS) based on both known and
novel genetic loci. Lastly, we aimed to investigate the relationship between the aggregated
effects of biomarker-influencing genetic factors on obesity and glycemic traits, to estimate
the degree to which this association is mediated by these biomarker levels. Investigating
these relationships among adolescents with a high burden of obesity could provide critical
insight into the biological mechanisms of obesity and downstream CMD during adolescence.

METHODS
Study population

Author Manuscript

The Santiago Longitudinal Study (SLS) originally began as a preventive trial for
infancy iron deficiency anemia (IDA), funded by National Institutes of Health (NIH-R01
HD014122).19 From 1991 to 1996, a total of 1,792 infants were recruited at community
clinics in lower/middle-class neighborhoods, in Santiago, Chile. Inclusion criteria for
the infancy study were term singleton birth, vaginal delivery, birth weight ≥3kg, and
absence of major perinatal health problems.19 Follow up studies occurred at 5, 10, and
16 years and included anthropometric measurement, psychosocial data, and developmental
assessments.20,21 At 16 years, 679 adolescents completed a study of risk for obesity and
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CMD that targeted participants with the most comprehensive data in childhood. Data
collected included anthropometric measures, cardiovascular risk and metabolic biomarkers
from fasting blood samples, and self-reported health-related behaviors. Complete phenotype
and genotype data were available for 543 (80%) of these participants. The study was
reviewed and approved or found to be exempt by Institutional Review Boards of the
University of California at San Diego, University of Michigan, University of North Carolina
at Chapel Hill, and the Institute of Nutrition and Food Technology, University of Chile.
Genetic data and quality control

Author Manuscript

Participants were genotyped on the Illumina Multiethnic Genotyping Array with imputation
to the 1000 Genomes Phase III AMR reference panel. Quality control included individual
call rate of > 90%, assessment of sex mismatch, relatedness, and ancestry outliers. Single
nucleotide polymorphisms (SNPs) with effect allele frequency (EAF)<0.05, indels, and
imputation quality score<0.5 were excluded, resulting in ~6 million SNPs that were assessed
for their association with the biomarkers.
Measurement
Metabolic biomarkers.—Fasting blood samples were obtained, stored at −80°C, and
analyzed. Enzyme-linked immunosorbent assay (ELISA) was used to measure adiponectin
and leptin levels (R&D Systems, Minneapolis, MN and DRG International, Inc., New Jersey,
NJ, respectively). The radioimmunoassay (RIA) technique was utilized to quantify ghrelin
and orexin-A levels (Phoenix Pharmaceuticals, Inc., Burlingame CA).

Author Manuscript

BF%.—Dual energy x-ray absorptiometry (DEXA) scan was used to measure body fat mass
(Lunar Prodigy Corp. Software: Lunar iDXA ENCORE 2011, Version 13.60.033, Madison,
WI). BF% was calculated as [100(%) × fat mass(kg)/total body mass (kg)].
Glycemic traits.—From overnight fasting blood, glucose and insulin levels were
quantified with an enzymatic colorimetric assay (QCA S.A., Amposta, Spain) and
radioimmunoassay (RIA DCP Diagnostic Products Corporation, LA), respectively. In
addition, IR was assessed based on continuous measure of homeostatic model assessment of
insulin resistance (HOMA-IR; calculated as [(glucose (mg/dL) × insulin (μUI/dL))/405]; a
value of HOMA-IR ≥ 2.6 can be diagnosed as insulin resistance.).22
Analytical approach

Author Manuscript

Genome-wide association tests.—We regressed four metabolic biomarkers on SNPs
using SUGEN 23, assuming an additive genetic model and adjusting for sex and population
substructure using the first 5 principal components (PCs). PCs were constructed by
EIGENSTRAT24 using genetic information of the participants. Serum adiponectin, ghrelin,
and orexin levels were natural log-transformed before regression analyses. Due to a
detection limit issue in measuring leptin levels, rank-based normalized residuals of a Tobit
regression model adjusting for sex were used in the genome-wide association analyses
for leptin levels. To correct for multiple testing, we considered SNPs with p-value <5
× 10−8 as demonstrating genome-wide significance, and those with a p-value <5 × 10−6
as demonstrating suggestive significance. We identified putative novel loci and reported
Pediatr Res. Author manuscript; available in PMC 2022 October 04.
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the lead SNP from all 1 MB regions of the genome-wide significant and/or suggestive
significant associations where no previous GWAS signal had been reported.
Validation of the GWAS findings.—For adiponectin and leptin levels, we investigated
if the SNPs identified from SLS demonstrated similar associations in a separate Mexican
American validation data set (see Supplementary Material for more information). We
considered a signal to be validated if the same SNP was associated with the metabolic
biomarker level at a Bonferroni-corrected significance level (p <0.05/the number of SNPs
tested for validation for each biomarker) with directional consistency.

Author Manuscript

Functional interrogation of putative novel signals.—Among validated SNPs, we
interrogated the potential candidate genes in each locus, selected based on 1) the evidence
of functional link to a genetic locus (SNP) and 2) the previous reports on plausible gene
functions. To examine the functional connection between a SNP and a gene, we queried the
expression quantitative trait loci (eQTLs) from NIH Genotype-Tissue Expression (GTEx)
project25 and biologically plausible gene functions using databases such as PubMeda, Online
Mendelian Inheritance in Manb, and GeneCardsc.
Transferability of known associations.—We described the transferability of known
associations for adiponectin and leptin in SLS, defined when the association was reported
with the exact SNP at nominal statistical significance (p <0.05) and directional consistency.
As of 12/15/2020, there were 48 and 15 previously reported SNPs associated with
adiponectin and leptin, respectively, at the genome-wide significance level. There were
no previously reported SNPs associated with ghrelin or orexin levels at genome-wide
significance.

Author Manuscript
Author Manuscript

Constructing PRS of adiponectin and leptin based on known and putative
novel loci.—Given our small sample size and our desire to assess the evidence of mediated
effects of genetic variants for these biomarkers on obesity and glycemic traits, we assessed
the aggregated effects of previously reported genetic loci for adiponectin and leptin levels
by constructing PRS. Since the previously reported SNPs were tag SNPs primarily identified
in studies of Europeans, we considered three different approaches to PRS construction: 1)
PRS constructed only by the previously reported SNPs (PRSReported), 2) PRS constructed
by the SLS-specific tagging SNPs of the known loci (i.e., the lowest p-value within +/−
500kb of the previously reported SNPs) (PRSSLS), and 3) PRS constructed by both SLSspecific previous signals and putatively novel signals from the current study (PRSSLS+Novel).
PRSReported was calculated by summing the number of biomarker-increasing alleles of the
previously reported SNPs. If there were more than two SNPs in linkage disequilibrium (LD)
(AMR r2>0.2), we only included one tag SNP that was directionally consistent and had the
lowest p-value among directionally consistent SNPs. If any of them were not directionally
consistent, we included the SNP with the lowest p-value. PRSSLS was defined as the number
of biomarker-increasing alleles of the SLS-specific SNPs with the lowest p-values from the

a https://pubmed.ncbi.nlm.nih.gov/
b https://www.ncbi.nlm.nih.gov/omim
c https://www.genecards.org/
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current study among variants within +/− 500kb of the known SNPs. When we observed
correlated SLS-specific SNPs (AMR r2>0.2), we only included the SNP with the lower
p-value for the association with the biomarker. PRSSLS+Novel was derived by summing up
the PRSSLS and the number of biomarker-increasing alleles of the SNPs with genome-wide
significance or suggestive significance from the current study.

Author Manuscript

Investigating the associations between the adiponectin and leptin levels and
the constructed PRS for the biomarker in the H/L population.—We evaluated the
aggregated genetic effects on adiponectin and leptin levels among SLS by regressing each
biomarker (for adiponectin, ghrelin, and orexin, natural log-transformed values; for leptin,
rank-based inverse normalized residuals of a Tobit regression adjusting for sex) on each PRS
assuming a linear relationship and assessing prediction model by comparing R2 (or adjusted
R2 for the models with covariates). Specifically, we compared four separate models for each
biomarker as follows: a model only including PRS of the biomarker (Model 1), a model
additionally including sex as a covariate (Model 2), a model additionally including the first
five PCs as covariates (Model 3), and a model additionally including the BMI Z-score
(Model 4).

Author Manuscript

Investigating the relationship between the aggregated effects of biomarker
influencing genetic factors on BF% and glycemic traits.—Adjusting for sex and
the first five PCs, we estimated the total effect of the metabolic biomarker PRS on BF%
and glycemic traits (fasting blood glucose (FBG), fasting blood insulin (FBI), and IR) and
the percent mediated through the biomarker levels using causal mediation analysis (PROC
CAUSALMED) in SAS 9.4 (SAS Institute Inc., Cary, NC).26,27 The proposed pathways,
both direct and indirect, from PRS to BF% and glycemic traits are shown in Figure S2.
For adiponectin and leptin levels, all three types of PRS were investigated; for ghrelin and
orexin levels only those suggestive signals identified in the GWAS herein were used. All
pathways, including those to the biomarker and those to the cardiometabolic trait, were
adjusted for sex and the first 5 PCs. To further account for the potential heterogeneities by
sex, sex-stratified sensitivity analyses were conducted. In each stratified analysis, age and
the first five PCs were included as covariates. For leptin, rank-based inverse normalized
residuals of leptin from a Tobit regression adjusting for age were included as mediator. And
for the other biomarkers, natural log-transformed biomarker levels were used as mediators.
Statistical significance was determined using Bonferroni-corrected p-values. The results of
sex-stratified analyses were presented in the supplementary tables (Table S12 – Table S15).

RESULTS
Author Manuscript

Descriptive statistics.
Table 1 reports the descriptive statistics from the 543 SLS participants (259 females)
included in the current analyses. The average levels of adiponectin, leptin, ghrelin, and
orexin were 11.3μg/mL (SD: 5.3), 11.7ng/mL (SD:13.5), 239.6pg/mL (SD: 151.0), and
16.7pg/mL (SD: 4.2), respectively. The descriptive characteristics of the validation sample
are shown in Table S1.
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No SNP-metabolic biomarker associations displayed genome-wide statistically significant
evidence of association. However, 8, 5, 13, and 8 loci displayed suggestive associations
with adiponectin, leptin, ghrelin, and orexin, respectively. The lead SNPs, nearest genes, and
corresponding p-values for adiponectin, leptin, ghrelin, and orexin are reported in Table 2.
Validation of putative novel signal.

Author Manuscript

Ten of 13 adiponectin- or leptin-associated SNPs were available in the validation set. Of
the examined genetic markers for validation (6 for adiponectin and 4 for leptin), only
the marker rs12066716 was found to be significantly associated (Bonferroni-corrected p
<0.00625 (=0.05/8)) with adiponectin with directional consistency [β(±SE) in the discovery
set: −0.181 ± 0.039, β(±SE) in the validation set: −0.191 ± 0.065], The other 9 signals
for adiponectin and leptin level were directionally consistent but not statistically significant
(Table S2).
Functional interrogation of putative novel signals.
For our validated adiponectin-associated SNP (rs12066716), we identified a candidate gene
demonstrating both functional links to an index SNP and plausible biological functions in
determining adiponectin level. The index SNP (rs12066716) is an eQTL for C1QTNF12
(C1q/TNF-related protein 12, CTRP12) in visceral adipose tissue (p for eQTL = 8.1 ×
10−5)d. CTRPs, including CTRP12 (the product of C1QTNF12), are a family of adiponectin
paralogs,28–30 thus the association between the gene and adiponectin is highly feasible.
Transferability of known associations.

Author Manuscript

For adiponectin, a total of 48 different SNPs have been reported for association with
adiponectin from 11 studies31–41, 44 of which were available in the current study (Table S3).
Thirty-five of these 44 SNPs displayed directionally consistent associations with adiponectin
levels, 8 of which displayed nominal statistical significance (p<0.05). Fifteen variants have
been associated with leptin levels with genome-wide significance from 3 studies42–44; 13 of
these variants were available in the current study (Table S4). Six of these 13 associations
were directionally consistent, but none were nominally significant (p<0.05).
Aggregated genetic influence on adiponectin and leptin levels

Author Manuscript

Adiponectin.—As some of the 44 available known SNPs are in LD with one another,
we selected 29 independent SNPs (AMR LD r2<0.2) and constructed PRSReported for
adiponectin (Table S5). We also identified 24 independent SLS-specific tagging SNPs in the
known loci by selecting the SNPs with lowest p-value for the association with adiponectin
levels within +/− 500kb of the reported SNPs (Table S7). All the 24 SLS-specific tagging
SNPs were independent of each known SNP (AMR LD r2<0.2). Using these 24 SLS-specific
tagging SNPs for the known loci, we generated PRSSLS. Lastly, we additionally summed
up the number of adiponectin-increasing alleles of the 8 putative novel variants from the
PRSSLS and generated adiponectin-PRSSLS+Novel. The prediction results of the natural log-

d https://www.gtexportal.org/home/snp/rs12066716
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transformed adiponectin levels by PRS were reported in Table 3. While the proportion
of variance explained by PRSReported was 0.035, the proportion of variance explained by
PRSSLS was 0.253 (Table 3). We further estimated the proportion of variance explained by
PRSSLS+Novel from the current study as 0.367. While the estimated variance explained is
likely to be biased upward because of winner’s curse, it is obvious that the SLS-specific
tagging SNPs better characterized the genetic effects of these loci on this biomarker (also
below for leptin) for our SLS population.

Author Manuscript

Leptin.—Among the 13 available known SNPs, we selected 7 independent SNPs (AMR
LD r2 <0.2) and constructed PRSReported for leptin levels (Table S6). We also identified 8
SLS-specific tagging SNPs of the known loci – i.e., SNPs with the lowest p-values within
+/− 500kb of the known variant – and constructed PRSSLS for leptin levels (Table S8). All
the 8 SLS-specific tagging SNPs are independent of the known SNPs (AMR LD r2<0.2).
Then, we summed up the number of leptin-increasing alleles of the 5 putative novel variants
from the PRSSLS and calculated PRSSLS+Novel. We predicted the rank-based normalized
residuals of Tobit regressed leptin level (sex as an explanatory variable) by using the three
PRS (Table 3). Whereas the variance explained by PRSReported was 0.001 (and the regression
coefficient was not significant with a significance level of 0.05), the variance explained by
PRSSLS was 0.082 and by PRSSLS+Novel was 0.206 (Table 3). It is possible that the R2 for
leptin was lower than for adiponectin partly due to fewer previous GWAS of leptin than
adiponectin.
Effects of the biomarker-associated genetic determinants on downstream BF% and
glycemic traits

Author Manuscript

Adiponectin.—FBI (p=0.0037), IR (p=0.0064) and BF% (p<0.0001) were significantly
associated with PRSSLS+Novel (Table 4). For FBI and IR, significant indirect effects (i.e.,
mediated through adiponectin levels) were noted. The mediated effects of adiponectin
PRSSLS+Novel on FBI and IR accounted for 79.0% (95% CL: 2.4, 155.5; p=0.04) and
83.2% (95% CL: −0.5, 166.8; p=0.05) of the overall effects, respectively. For BF%, we also
found evidence of mediation, but the proportion of mediated effects over the total effects
was only 46.7% (95% CL: 2.4, 90.9; p=0.04). Given the wide confidence interval of these
estimates, point estimate should be interpreted with caution. In terms of direction of effects,
both directly and indirectly the adiponectin-increasing effects appeared to be metabolically
protective (decrease in FBI, IR, and BF%). For PRSSLS, the total effects on FBI and BF%
were estimated as being significant as for PRSSLS+Novel, but for PRSReported, none of them
was significantly affected by the PRS (Table S9).

Author Manuscript

Leptin.—FBI (p=0.0014), IR (p=0.0043), and BF% (p<0.0001) were significantly affected
by the leptin PRSSLS+Novel (Table 4). The total effect of leptin-increasing PRS was
associated with poorer metabolic outcomes (i.e., increase in FBI, IR, and BF%). For FBI and
IR, the estimate of the direct effect of PRS on leptin was negative and the estimate of the
indirect effect of PRS on the CMD health outcome through leptin was positive. Therefore,
the indirect pathway through leptin accounted for most of this association between FBI and
IR. For BF%, where both direct and indirect associations were positive, the proportion of
mediated effects was 96.9% (95% CL: 65.2, 128.5; p<0.01). For PRSSLS, only the total
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effect on BF% was significant (also associated with worse metabolic outcomes); none of
the hypothetical downstream BF% and glycemic traits were significantly associated with
PRSReported (Table S10). According to the results from sex-stratified analyses, the total
effects of leptin PRSSLS+Novel on FBI and IR are largely driven by females, however, the
indirect effects mediated through leptin are comparable–in terms of direction, magnitude,
and significance – among females and males (Table S13).

Author Manuscript

Ghrelin.—FBI (p<0.0001) and IR (p<0.0001) were significantly affected by the ghrelin
PRS based on the putative novel variants from the current study (Table 4) with ghrelinincreasing PRS associated with overall decreases in IR. As with leptin, we found differences
in the direction of the association between direct and indirect effects. Higher PRS were
indirectly related with lower FBG (−0.223 [95% CI: (−0.286, −0.161)]) and IR (−0.232
[95% CI: (−0.295, −0.169)]), and the total association was similar in magnitude even after
accounting for the direct effects.
Orexin.—None of the cardiometabolic traits were affected by the orexin-increasing PRS
(Table 4).

DISCUSSION

Author Manuscript

The identification of genetic mechanisms influencing metabolic biomarkers has the potential
to identify important pathways for obesity and its downstream consequences. Yet, the bulk
of obesity research has focused on how genes relate to BMI and waist circumference,
instead of on relationships with eating behaviors and/or mechanistic biomarkers which may
have early influences on the development of obesity, through appetite for example. Further
still, most extant data has primarily focused on homogeneous middle-aged adults, with very
few genetic studies on culturally and ancestrally diverse adolescents. The current study
identified 34 suggestive novel genetic signals associated with four metabolic biomarkers and
validated one novel signal associated with adiponectin level. In addition, we revealed that
associations between biomarkers and aggregated genetic effects based on known variants
were improved when study-specific tag SNPs for known loci and novel variants were
included in the PRS. This implicates the need for ancestry-specific studies to validly capture
aggregated genetic effects across populations. Lastly, we demonstrated that metabolic
biomarker-influencing genetic factors were also associated with some CMD risk factors,
especially with FBI and IR (for adiponectin, leptin, and ghrelin) and BF% (for adiponectin
and leptin), implicating causal roles of these biomarkers in obesity and IR as early as
adolescence.

Author Manuscript

Although our study did not demonstrate novel genome-wide significant signals for appetite
markers, likely due to insufficient power, 34 putative novel signals with suggestive evidence
for association with metabolic biomarkers were mapped, with the rs12066716 adiponectin
association validated in a H/L adult population (p<0.00625) despite the age differences
between the two study populations. While the SNP is intronic to TTL10, it is associated
with gene expression in several other nearby genes in adipose tissue. Notably, rs12066716
is an eQTL for C1QTNF12, which encodes CTRP12 (also called adipolin), a member of
the family of adiponectin paralogs.28,30,45,46 CTRP12 improves insulin sensitivity29 and has
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been shown to correlate with adiponectin levels (r=0.34) 47 In addition, CTRP12 levels are
currently being evaluated as a diagnostic biomarker for T2D48 Finally, other studies have
demonstrated that CTRP12 levels were lower among patients with coronary artery disease.47

Author Manuscript
Author Manuscript

We found that little to none of the variance in adiponectin and leptin levels were explained
by PRS based on the exact reported SNPs from the literature, likely due to the ancestral
difference between our population (i.e., mainly European vs. H/L) and published studies.
Once we substituted SLS-specific tagging SNPs of the known loci for the reported SNPs,
the prediction performance of the PRS improved substantially (R2 0.035 to 0.253 for
adiponectin and 0.001 to 0.082 for leptin). We conducted permutation testing to place our
adiponectin-PRSSLS findings in context. We randomly selected 24 SNPs among all SNPs
that displayed significant association (p<0.05) with adiponectin in our GWAS. We then
constructed the PRS (the number of risk alleles) from each these SNPs and calculated the
R-square values from each model. Repeating this simulation 1000 times, we observed the
distribution of R-square values (maximum: 0.220; range: 0.125 – 0.220; Figure S4). All
R-square values were of smaller magnitude than our adiponectin-PRSSLS estimate (0.253).
Thus, our results demonstrate that the proportion of variation explained by adiponectinPRSSLS was greater than chance, likely an overestimation as well. This finding demonstrates
the need for valid ancestry-specific tagging SNPs for PRS. Furthermore, since we identified
additional improvement of PRS’ performance after incorporating the putative novel signals,
large-scale studies for diverse populations to discover additional genetic loci associated with
metabolic biomarker are warranted. However, it should be noted that the predictions by
PRSSLS and PRSSLS+Novel were likely to be overestimated because of the overlap between
the discovery set of the associations and the validation set for the association. Nonetheless,
as illustrated in our previous study49, the current findings also underscore the importance of
considering genetic diversity across different cohorts, and the influence of this diversity on
unique underpinnings to disease in future application of PRS to diverse ethnic groups.50
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For adiponectin, leptin, and ghrelin, PRS of biomarkers were simultaneously associated with
FBI, IR and BF% (except for ghrelin) among H/L adolescents. These common associations
may suggest shared genetic pathways, at least to a certain degree, between metabolic
biomarkers and CMD as early as adolescence. Many of the significant overall effects
included significant mediated effect by metabolic biomarkers (FBI, IR, and BF% for leptin
and adiponectin, and FBI and IR for ghrelin), and this implies that each metabolic biomarker
might be somewhere on the causal pathways from the biomarker-determining genetic factors
to the CMD risk factors—i.e., the metabolic biomarkers are causally associated with the
CMD risk factors—if our assumption on the hypothetical causal relationship (see Figure S2)
is valid. Notably, FBI and IR are closely associated with PRS for adiponectin, leptin, and
ghrelin through indirect effects. Since IR is considered a root cause of various CMD 51,
it is crucial to elucidate the roles of these metabolic biomarkers in developing IR. For the
significant mediated effects on BF% for adiponectin and leptin, our findings also suggest an
early causal effect of adiponectin and leptin on body fat, suggesting an importance of these
biomarkers for the development of obesity at a very young age. Such findings may have
relevance for the timing of planning interventions.
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The observed significant indirect effects on FBI, IR, and BF% support the protective roles of
adiponectin in cardiometabolic health. While inverse associations of plasma adiponectin
with IR and adiposity have been well established 52,53, the findings from mendelian
randomization studies to assess the causal relationships between adiponectin and IR (or
insulin sensitivity) and between adiponectin and BMI have been contradictory 54–57 or
unsupported 58. Such findings may be related to weak genetic instruments, population
stratification bias, genetic pleiotropy, and LD. Although our analysis has not formally
assessed causal relationships between these biomarkers, our data support a potential
influence of adiponectin on FBI, IR, and BF% by the presence of significant indirect effects
of adiponectin-associated genetic factors mediated by adiponectin levels. In addition, for
BF%, the effect sizes of the direct (β = −0.072 despite not meeting the significance criteria;
p = 0.084) and indirect effect (β = −0.063, p = 0.018) were comparable. This implies the
presence of other pathways from the adiponectin-associated genes to BF% independent of
adiponectin. Further studies investigating potential common pathways shared between BF%
and adiponectin levels are needed.
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For the downstream effect of leptin-influencing genetic variants on adiposity, a previous
study reported that a leptin-decreasing allele (rs17151919-A) was associated with higher
BMI during early childhood (under 8-year) 44 However, our results demonstrated a leptinincreasing PRS was associated with higher BF%. Such results may be understood in
the context of distinct leptin effects across the life-course and in the context of poor
cardiometabolic health. Although leptin typically inhibits appetite and increases energy
expenditure59, individuals with poor cardiometabolic health tend to have higher circulating
leptin levels due to low leptin sensitivity60 – i.e., leptin resistance. Since the previous study
and our results focused on early childhood and late adolescence, respectively, the opposite
direction of the association between leptin-influencing genetic variants and adiposity might
have been driven by the development of leptin resistance.
For ghrelin, similar patterns with adiponectin were demonstrated except for BF%. This
implicates the potential protective roles of circulating ghrelin in cardiometabolic traits
especially for insulin biology. In line with this finding, many previous studies including
a meta-analysis61 on the association between ghrelin and IR in obesity reported the negative
correlation among people with obesity. Thus, our study adds to the body of literature that
supports ghrelin’s role in glucose metabolism, but the mechanisms by which circulating
ghrelin levels play roles in regulating insulin sensitivity need to be further studied.

Author Manuscript

Overall, our results contribute to the mechanistic evidence of obesity-risk genes influencing
adiposity via the appetite regulatory system, as previously shown for monogenic obesity
disorders, which, without exception, involve disturbances of appetite leading to severe earlyonset obesity.62 A substantial evidence base of prospective studies links impaired satiety
mechanisms to excessive weight gain63–65, and bivariate twin analyses are consistent with
common genetic pathways underlying satiety responsiveness and weight in infancy66. This
suggests that genetically susceptible individuals are particularly vulnerable to the abundance
of highly palatable food in the modern obesogenic environment.
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The major strength of this study is the availability of four metabolic biomarkers in an
adolescent H/L population at high risk for obesity and downstream CMD. In particular,
genome-wide studies of ghrelin and orexin are rare. For adiponectin and leptin, we also
leveraged the known information from the previous studies to assess the aggregated genetic
effects. Lastly, we extensively investigated cross-trait associations of biomarker-influencing
genetic loci with other CMD risk factors. There are notable limitations to our study,
including the modest sample size and the lack of availability of studies to replicate our
findings. Nine out of 10 putative novel signals for adiponectin and leptin level were not
replicated from the validation data set, which could be related to the distinct admixture
patterns across Mexican Americans and Chileans, the differences in age across the data sets,
or small sample sizes. In addition, PRSSLS and PRSSLS+Novel may have overestimated the
aggregated genetic effects and cross-trait associations with BF%, FBI, and IR. Furthermore,
as analyses were conducted cross-sectionally, it is difficult to determine temporality among
traits, e.g., metabolic biomarkers and cardiometabolic traits, and the possibilities of reverse
causation between biomarker level and cardiometabolic traits.
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In conclusion, our study identified several putatively novel genetic variants associated with
the metabolic biomarkers with substantial phenotypic variance explained by SLS-specific
PRS. We also demonstrated that some of the aggregated genetic factors may be directly
linked to BF%, FBI, and IR or mediated through metabolic biomarkers. Our findings
reinforce a need for longitudinal analyses to confirm the genetic determinants regulating
metabolic homeostasis and their further influence on cardiometabolic disorder development.
From a public health standpoint, such findings are critical, as once cardiometabolic health
is established in adolescence, it is very difficult to reverse. Thus, findings from this study
yielded important information on biological mechanisms and candidates for prevention
efforts, especially relevant in this high-risk ancestrally diverse population.
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•

This study characterized the genetic underpinnings of four metabolic
hormones and investigated their potential influence on adiposity and insulin
biology among Hispanic/Latino adolescents.

•

Fasting blood insulin and insulin resistance were associated with polygenic
risk score (PRS) for adiponectin, leptin, and ghrelin, with evidence of some
degree of mediation by the biomarker levels. Body fat percent (BF%) was
also associated with PRS for adiponectin and leptin. This provides important
insight on biological mechanisms underlying early metabolic dysfunction and
reveals candidates for prevention efforts.

•

Our findings also highlight the importance of ancestrally diverse populations
to facilitate valid studies of the genetic architecture of metabolic biomarker
levels.
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Distributions of variables among 16-year follow-up of the Santiago Longitudinal Study (SLS)
a

Total (N=543)

Variable

Mean

SD

16.8

0.3

Body Mass Index (BMI) (kg/m2)

23.8

4.6

BMI Z-scores

0.5

1.0

Adiponectin (μg/mL)

11.3

5.3

Leptin (ng/mL)

b

11.7

13.5

Ghrelin (pg/mL)

239.6

151.0

(N=542; 1 missing female) Orexin (pg/mL)

16.7

4.2

Fasting blood glucose (mg/dL)

88.4

9.8

Fasting blood insulin (μUI/dL)

8.1

5.6

Insulin resistance [HOMA-IR (glucose × insulin/405)]

1.8

1.3

Body fat percent (%) (N=537; 5 missing females and 1 missing male)

28.9

10.7

Age (years)
Anthropometric variables

Metabolic biomarkers

Author Manuscript

Glycemic traits

c

a

259 females (47.7%) and 284 males (52.3%)

b

Leptin levels in females: 18.8 ng/mL (SD: 14.7); leptin levels in males: 5.2 ng/mL (SD: 8.0)
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c

HOMA-IR: homeostatic model assessment of insulin resistance
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Ghrelin

Leptin

5
13

rs17130858
rs407484
rs33601

C3orf31
VCAN

3
7
10
11
12
16
20
21

rs11083829
rs34056816
rs8026541
rs233521
rs77137714
rs62063332
rs12144587
rs76491617
rs67899970
rs181846169
rs4535245
rs6966968
rs34988394
rs4938201
rs11175889
rs17385192
rs6076964
rs11701620
rs12159453

PNMAL1
ZNF804B

SQRDL (SQOR)
CDH5

LOC100506172
MIR4739

LOC100129138
ADAM30
PSEN2
CNTNAP5
KCNH8
NXPH1
R4B11FIP2
CADM1
RPSAP52
CDH11
FERMT1
CRYAA

LOC100271722
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22

2

1

1

1

17

16

16

15

7

19

14

rs2992893
rs17098985

CLDN10
FLJ22447

3

1

1

rs59559185

AK5
LRRC8C

rs12066716

CHR
1

TTLL10

Adiponectin

Lead SNP

a

Nearest gene

GWAS Traits

46433442

44601373

6210743

63892792

66117678

115218713

119738984

8840378

19541306

124237624

227092656

120434349

106005238

77635587

73378933

66282923

46695491

89190522

46967169

62092745

96044769

82773175

11944316

90167923

77825925

1123434

BP

A/G

G/C

T/C

G/T

G/T

G/A

T/C

G/A

A/G

T/C

T/C

C/T

G/T

G/A

T/C

A/G

T/C

C/T

C/A

T/C

C/T

A/G

A/T

G/A

A/G

A/T

EA/OA

0.08

0.06

0.06

0.24

0.32

0.39

0.16

0.10

0.14

0.05

0.14

0.15

0.56

0.09

0.14

0.80

0.72

0.06

0.74

0.13

0.52

0.66

0.10

0.25

0.18

0.17

EAF

−0.305

0.346

0.341

0.184

0.173

−0.162

0.234

0.295

−0.222

0.419

0.228

−0.239

−0.154

−0.567

0.409

0.350

0.367

0.748

−0.174

−0.236

−0.148

0.144

−0.271

0.158

0.182

−0.181

BETA

0.064

0.073

0.075

0.039

0.036

0.035

0.050

0.059

0.048

0.087

0.049

0.051

0.033

0.124

0.088

0.076

0.069

0.161

0.036

0.045

0.030

0.031

0.053

0.033

0.039

0.039

SE

1.58E-06

1.84E-06

4.65E-06

2.05E-06

1.86E-06

3.31E-06

2.83E-06

5.28E-07

3.86E-06

1.24E-06

4.05E-06

2.80E-06

4.07E-06

4.64E-06

3.70E-06

4.29E-06

1.14E-07

3.47E-06

1.48E-06

1.29E-07

7.02E-07

4.94E-06

4.00E-07

1.38E-06

2.55E-06

3.04E-06

p-value

Lead SNPs with suggestive significance (p < 5.00E-06) associated with four appetite/metabolic biomarkers from the GWA analyses in participants of SLS

Author Manuscript
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rs11702068
rs9608521

SIK1
MIAT
22

21

18

27199237

44768217

59468629

75734152

26977581

407189

74503190

56891592

BP

T/C

T/C

G/A

C/T

T/C

T/C

C/T

G/A

EA/OA

0.18

0.19

0.07

0.06

0.17

0.08

0.08

0.16

EAF

−0.089

−0.093

0.148

−0.162

0.108

−0.132

−0.126

−0.099

BETA

0.019

0.020

0.031

0.033

0.020

0.029

0.027

0.021

SE

3.18E-06

2.27E-06

2.46E-06

7.10E-07

6.83E-08

4.22E-06

3.62E-06

2.30E-06

p-value

Validated signal (In the validation set: β = −0.191 ± 0.065, P = 0.003, EA = A, and EAF = 9%)

a

SLS, Santiago Longitudinal Study; CHR, chromosome; BP, base pair; EA, effect allele; OA, other allele; EAF, effect allele frequency; SE, standard error

rs34264102

RNF152

17

15

rs8036016
rs56201168

4

GABRB3

2

rs3771728
rs60941356

SLC4A5
ABCA11P

FLJ45079

1

rs944844

PPAP2B

CHR

Orexin

Author Manuscript
Lead SNP

Author Manuscript

Nearest gene

Author Manuscript
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a

Author Manuscript

Author Manuscript

Author Manuscript
0.025
0.025
0.022

−0.017
−0.015
−0.020

3

4

0.006

0.029

2

0.006

0.028

4

0.006

3

0.006

0.028

d

0.027

SE

2

d

Beta

1

c
Model

0.3744

0.5387

0.4919

<0.0001

<0.0001

<0.0001

<0.0001

d

P

PRSReported

0.222

0.018

0.001

0.167

0.101

0.092

0.035

R2

0.212

0.007

−0.001

0.155

0.089

0.089

0.034

Adj. R2

0.160

0.189

0.190

0.085

0.090

0.088

0.089

Beta

0.025

0.027

0.027

0.006

0.006

0.006

0.007

SE

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

P

PRSSLS

0.278

0.098

0.082

0.352

0.324

0.305

0.253

R2

0.268

0.088

0.080

0.342

0.316

0.302

0.252

Adj. R2

0.194

0.230

0.231

0.079

0.082

0.080

0.080

Beta

0.018

0.019

0.020

0.004

0.004

0.004

0.005

SE

R2

0.361

0.220

0.206

0.463

0.443

0.421

0.367

0.352

0.212

0.204

0.455

0.436

0.419

0.366

Adj. R2
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Leptin: [Model 2] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~ PRS; [Model 3] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~
PRS + PC1 + PC2 + PC3 + PC4 + PC5; [Model 4] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~ PRS + PC1 + PC2 + PC3 + PC4 + PC5 + BMI Z-score

•

Beta: a regression coefficient for PRS; SE: standard error of the regression coefficient; P: p-value

d

Adiponectin: [Model 1] log (Adiponectin levels) ~ PRS; [Model 2] log (Adiponectin levels) ~ PRS + Sex; [Model 3] log (Adiponectin levels) ~ PRS + Sex + PC1 + PC2 + PC3 + PC4 + PC5;
[Model 4] log (Adiponectin levels) ~ PRS + Sex + PC1 + PC2 + PC3 + PC4 + PC5 + BMI Z-scores

•

Models:

Adiponectin: natural log-transformed adiponectin level; leptin: rank-based normalized values of residuals from Tobit regression (sex-adjusted) for leptin levels.

b

previously reported SNP; PRSSLS+Novel: PRS constructed by additional putative novel SNPs from the current study in addition to the PRSSLS

c

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

P

PRSSLS+Novel

PRSReported: polygenic risk score (PRS) constructed by the previously reported SNPs; PRSSLS: PRS constructed by SLS-specific tagging SNPs (with the lowest p-value) within +/− 500kb region of the

a

Leptin

Adiponectin

b
Biomarker

Associations of adiponectin and leptin levels with PRSReported, PRSSLS, and PRSSLS+Novel in SLS participants
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−0.117

HOMA-IR

0.123

HOMA-IR
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−0.215

HOMA-IR

FBG

Glycemic Traits
−0.069

−0.064

−0.217

FBI

Orexin PRS

BF%

−0.061

FBG

Glycemic Traits

0.185

0.137

FBI

Ghrelin PRS

BF%

−0.032

FBG

Glycemic Traits

−0.135

−0.124

FBI

Leptin PRS

BF%

0.001

FBG

Glycemic Traits

Adiponectin PRS

Beta

−0.150

−0.127

−0.298

−0.299

−0.142

0.123

0.039

0.053

−0.114

−0.198

−0.201

−0.208

−0.081

0.012

0.000

−0.133

−0.134

0.020

0.248

0.207

0.221

0.050

−0.071

−0.033

−0.040

0.082

95% CL

Total effect

a

−0.026
−0.020
−0.072

b
b
b

−0.021
0.006

b
b

0.0939

0.0499

<0.0001

<0.0001

0.1381

<0.0001

0.0043

0.017

b

−0.059

0.029

0.007

b

0.057

−0.009

b

0.0014

−0.064

0.4406

<0.0001

0.0064

0.0037

0.026

Beta

0.9831

P

a

−0.145

−0.049

−0.080

−0.089

−0.042

−0.054

−0.110

−0.098

−0.154

−0.153

−0.128

−0.134

−0.080

0.026

0.106

0.113

0.103

0.156

0.066

0.068

0.079

0.027

0.010

0.088

0.082

0.131

95% CL

Direct effect

−0.010

−0.092

−0.232

−0.223

−0.118

0.180

0.144

0.146

0.032

−0.063

−0.097

−0.098

−0.025

Beta

−0.038

−0.139

−0.295

−0.286

−0.178

0.139

0.098

0.100

−0.008

−0.115

−0.167

−0.167

−0.092

0.018

−0.046

−0.169

−0.161

−0.058

0.221

0.190

0.192

0.071

−0.011

−0.028

−0.029

0.042

95% CL

a

Indirect effect

The effects of biomarker PRS on downstream body fat percent (BF%) and glycemic traits (fasting blood glucose (FBG), fasting blood insulin (FBI), and
insulin resistance (IR)) in SLS participants.
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0.011

−0.013
−0.053

−0.097

−0.085

0.075

0.071

0.083

0.7320

0.7588

0.9872

0.031

0.019

0.032

Beta

−0.037

−0.069

−0.056

0.099

0.108

0.121

95% CL

−0.020

−0.033

−0.033

Beta

−0.042

−0.063

−0.063

Mediator: standardized natural log-transformed biomarker levels (or rank-based normalized values of residuals from Tobit model (sex-adjusted) for leptin levels)

Covariates: Sex, PC1, PC2, PC3, PC4, PC5

•

•

Significant total effects of biomarker PRS on downstream BF% and glycemic traits (after correction for multiple testing p < 0.0125 (=0.05/4)

b

Model: Standardized Natural log transformed glycemic traits or BF% ~ Standardized biomarker-PRS + standardized natural log-transformed biomarker levels (or rank-based normalized
values of residuals from Tobit model (sex-adjusted) for leptin levels) + Sex + PC1 + PC2 + PC3 + PC4 + PC5

•

Total effect: The overall effects of the biomarker PRS (constructed by putative novel SNPs in addition to SLS-specific tagging SNPs) on BF% or glycemic traits; direct effect: the effect of the biomarker
PRS on BF% or glycemic traits after adjusting for the biomarker levels; indirect effect: the effect of the biomarker PRS on BF% or glycemic traits mediated through biomarker levels. All effects were
estimated after adjusting for sex and 5 principal components of participants’ genetic composition. Adiponectin levels, ghrelin levels, orexin levels, FBG, FBI, and HOMA-IR were natural log-transformed.
For leptin, rank-based inverse normalized residuals of a Tobit regression model adjusting for sex were used to account for the limit of detection issue. All the exposures, mediators, and outcomes were
standardized.

a

0.003

−0.003

−0.003

95% CL

a

Indirect effect

Note: HOMA-IR (homeostatic model assessment of insulin resistance); 95% CL (Wald 95% Confidence Limits)

BF%

−0.001

FBI

Author Manuscript

HOMA-IR

95% CL

P

Author Manuscript
Beta

a

Author Manuscript
Direct effect

Author Manuscript

a
Total effect
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